Financings in Brief: ESC Medical Systems
This article was originally published in The Gray Sheet
Executive Summary
ESC Medical Systems: Commences offering of $100 mil. in convertible subordinated notes due 2002. "The notes will have a coupon rate of 6% and be convertible into the company's ordinary shares at a conversion price equal to $46.55 per share," the Yokneam, Israel-based dermatologic laser firm states. ESC plans to use net proceeds for working capital and "general corporate purposes, which may include acquisitions," the firm states...
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.